Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talzenna with Temozolomide or Irinotecan in Advanced Solid Tumors
NCT02049593Phase 1Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jun 2014
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of talazoparib in solid tumor (2 arms), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Jun 2014; status: completed.
02
Drugs
talazoparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02049593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049593.